# ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)

> **NCT05279417** · PHASE2 · COMPLETED · sponsor: **Aclaris Therapeutics, Inc.** · enrollment: 251 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** ATI-450 50 mg oral tablet BID
- **DRUG:** Placebo oral tablet
- **DRUG:** Methotrexate
- **DRUG:** ATI-450 20 mg oral tablet BID

## Key facts

- **NCT ID:** NCT05279417
- **Lead sponsor:** Aclaris Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-01
- **Primary completion:** 2023-09-05
- **Final completion:** 2023-10-11
- **Target enrollment:** 251 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279417, "ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05279417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*